Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers

Gastrointestinal Endoscopy

Volumn 80, Issue 6, 2014, Pages 984-991

  Timmer, Margriet R ^a,b   Brankley, Shannon M ^a   Gorospe, Emmanuel C ^a   Sun, Gang ^a   Lutzke, Lori S ^a   Iyer, Prasad G ^a   Halling, Kevin C ^a   Krishnadath, Kausilia K ^b   Wang, Kenneth K ^a  

^a MAYO CLINIC   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MYC PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 217; GENETIC MARKER; TRANSACTIVATOR PROTEIN; ZNF217 PROTEIN, HUMAN;

ABLATION THERAPY; AGED; ARGON PLASMA COAGULATION; ARTICLE; BALLOON CATHETER; BARRETT DYSPLASIA; BARRETT ESOPHAGUS; COHORT ANALYSIS; ENDOSCOPIC SURGERY; ENDOSCOPIC THERAPY; ESOPHAGUS DYSPLASIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE LOCUS; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; CATHETER ABLATION; ESOPHAGUS; GENETIC MARKER; GENETICS; MIDDLE AGED; MUCOSA; ONCOGENE MYC; PROPORTIONAL HAZARDS MODEL; PROTO ONCOGENE; REMISSION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

AGED; BARRETT ESOPHAGUS; CATHETER ABLATION; COHORT STUDIES; ESOPHAGUS; FEMALE; GENES, ERBB-2; GENES, MYC; GENES, P16; GENETIC MARKERS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TRANS-ACTIVATORS; TREATMENT OUTCOME;

EID: 84920161662     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2014.06.023     Document Type: Article

References (31)

1. P. Sharma, G.W. Falk, and A.P. Weston Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus Clin Gastroenterol Hepatol 4 2006 566 572
2. L.M. Brown, S.S. Devesa, and W.-H. Chow Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age J Natl Cancer Inst 100 2008 1184 1187
3. N.J. Shaheen, B.F. Overholt, and R.E. Sampliner Durability of radiofrequency ablation in Barrett's esophagus with dysplasia Gastroenterology 141 2011 460 468
4. R.E. Pouw, K. Wirths, and P. Eisendrath Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett's esophagus with early neoplasia Clin Gastroenterol 8 2010 23 29
5. B.F. Overholt, K.K. Wang, and J.S. Burdick Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia Gastrointest Endosc 66 2007 460 468
6. R.J. Haidry, J.M. Dunn, and M.A. Butt Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry Gastroenterology 145 2013 87 95
7. Anders M, Bähr C, El-Masry MA, et al. Long-term recurrence of neoplasia and Barrett's epithelium after complete endoscopic resection. Gut. Epub 2014 Jan 3.
8. W.J. Bulsiewicz, H.P. Kim, and E.S. Dellon Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett's esophagus Clin Gastroenterol Hepatol 11 2013 636 642
9. A.M. Rygiel, F. Milano, and F.J. Ten Kate Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-Adenocarcinoma sequence of Barrett's esophagus Cancer Epidemiol Biomark Prev 17 2008 1380 1385
10. E.G.B. Fritcher, S.M. Brankley, and B.R. Kipp A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus Hum Pathol 39 2008 1128 1135
11. P.S. Rabinovitch, G. Longton, and P.L. Blount Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables Am J Gastroenterol 96 2001 3071 3083
12. K. Schulmann, A. Sterian, and A. Berki Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-Associated neoplastic progression and predicts progression risk Oncogene 24 2005 4138 4148
13. B.J. Reid, L.J. Prevo, and P.C. Galipeau Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression Am J Gastroenterol 96 2001 2839 2848
14. P.C. Galipeau, X. Li, and P.L. Blount NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma PLoS Med 4 2007 e67
15. E.L. Bird-Lieberman, J.M. Dunn, and H.G. Coleman Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus Gastroenterology 143 2012 927 935.e3
16. Z. Jin, Y. Cheng, and W. Gu A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus Cancer Res 69 2009 4112 4115
17. L.M. Merlo, N.A. Shah, and X. Li A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma Cancer Prev Res (Phila) 3 2010 1388 1397
18. S.M. Brankley, E.G.B. Fritcher, and T.C. Smyrk Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma Hum Pathol 43 2012 172 179
19. M.T. Barrett, C.A. Sanchez, and L.J. Prevo Evolution of neoplastic cell lineages in Barrett oesophagus Nat Genet 22 1999 106 109
20. M. Hage, P.D. Siersema, and K.J. Vissers Molecular evaluation of ablative therapy of Barrett's oesophagus J Pathol 205 2005 57 64
21. S.S. Zeki, R. Haidry, and T.A. Graham Clonal selection and persistence in dysplastic Barrett's esophagus and intramucosal cancers after failed radiofrequency ablation Am J Gastroenterol 108 2013 1584 1592
22. J.M. Dunn, G.D. Mackenzie, and D. Oukrif Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy Br J Cancer 102 2010 1608 1617
23. G.A. Prasad, K.K. Wang, and K.C. Halling Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus Gastroenterology 135 2008 370 379
24. S.M. Brankley, K.K. Wang, and A.R. Harwood The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus J Mol Diagn 8 2006 260 267
25. S.E. Attwood, C.J. Lewis, and S. Caplin Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus Clin Gastroenterol Hepatol 1 2003 258 263
26. C. Guarner-Argente, T. Buoncristiano, and E.E. Furth Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication Gastrointest Endosc 77 2013 190 199
27. W.D. Lyday, F.S. Corbett, and D.A. Kuperman Radiofrequency ablation of Barrett's esophagus: outcomes of 429 patients from a multicenter community practice registry Endoscopy 42 2010 272 278
28. R.A. Ganz, B.F. Overholt, and V.K. Sharma Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. multicenter registry Gastrointest Endosc 68 2008 35 40
29. O. Pech, A. Behrens, and A. May Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus Gut 57 2008 1200 1206
30. B.J. Reid, D.S. Levine, and G. Longton Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets Am J Gastroenterol 95 2000 1669 1676
31. S.J. Spechler, P. Sharma, and R.F. Souza American Gastroenterological Association medical position statement on the management of Barrett's Esophagus Gastroenterology 140 2011 1084 1091